WAVEMAN · COMPANY

GPCR · Structure Therapeutics Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

GPCR

Name: Structure Therapeutics Inc. (GPCR) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Structure Therapeutics Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001888886

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

105

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

CONVERSIONS · 180D

codes C/M, not in net · $30.2K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

105 funds added or opened last quarter

more than 67% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

2.8% of shares outstanding short · 11.4 days to cover · settled 2026-07-31

below 58% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

105 funds added or opened positions in the latest 13F quarter, of 193 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +135.8%

+135.8%12M

FORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows 105 funds added last quarter, $1.7M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Structure Therapeutics Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

7,810,306.0 sh

$419.2M

WELLINGTON MANAGEMENT GROUP LLP

7,379,433.0 sh

$396.1M

Avoro Capital Advisors LLC

6,555,555.0 sh

$351.8M

Jupiter Topco LLC

5,204,212.0 sh

$279.3M

Deep Track Capital, LP

4,740,072.0 sh

$254.4M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

XICHEN LIN

FILED 2026-06-25

$1.7M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

TrueShares Technology, AI & Deep Learning ETF

$1.7M POSITION · AS OF 2026-03-31

5.8%

Aggressive Growth Portfolio

$16.6M POSITION · AS OF 2026-04-30

2.9%

ALPS Medical Breakthroughs ETF

$3.4M POSITION · AS OF 2026-02-28

2.5%

Roundhill GLP-1 & Weight Loss ETF

$1.2M POSITION · AS OF 2026-03-31

2.4%

American Century Focused Dynamic Growth ETF

$3.6M POSITION · AS OF 2026-02-28

1.1%

Fidelity Advisor Biotechnology Fund

$19.9M POSITION · AS OF 2026-04-30

1.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
OPERATING INCOME	$-176.6M	$-158.2M	$-102.8M	$-52.6M
NET INCOME	$-141.2M	$-122.5M	$-89.6M	$-51.3M
EPS (DILUTED)	-0.80	-0.78	-0.81	-5.51
OPERATING CASH FLOW	$-222.2M	$-116.6M	$-79.5M	$-46.1M
CASH	$799.6M	$169.5M	$129.8M	$26.1M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE